Rate Video

ASH 2018 | MRD highlights in myeloma from ASH 2018

Ola Landgren

ASH 2018

Multiple Myeloma

Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, gives his insight into the measurable residual disease (MRD) data from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

The mutagenic impact of melphalan in myeloma

Ola Landgren • 23 Aug 2021

What role will minimal residual disease testing play in multiple myeloma?

Ola Landgren • 22 Apr 2016

Effects of lenalidomide maintenance therapy and the immune microenvironment in patients with myeloma

Ola Landgren • 11 Dec 2021

Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM